TY - JOUR
T1 - Very Early Recurrence After Curative-Intent Surgery for Gastric Adenocarcinoma
AU - Spolverato, Gaya
AU - Capelli, Giulia
AU - Mari, Valentina
AU - Lorenzoni, Giulia
AU - Gregori, Dario
AU - Poultsides, George
AU - Fields, Ryan C.
AU - Weber, Sharon M.
AU - Votanopoulos, Konstantinos
AU - Cho, Clifford S.
AU - He, Jin
AU - Maithel, Shishir K.
AU - Pucciarelli, Salvatore
AU - Pawlik, Timothy M.
N1 - Publisher Copyright:
© 2022, Society of Surgical Oncology.
PY - 2022/12
Y1 - 2022/12
N2 - Background: Recurrence after curative-intent surgery can occur in more than 50% of gastric cancer (GC) patients. We sought to identify predictors of very early recurrence (VER) among GC patients who underwent curative-intent surgery. Methods: A multi-institutional database of GC patients undergoing curative-intent surgery between 2000 and 2020 at 8 major institutions was queried. VER was defined as local or distant tumor recurrence within 6 months from surgery. Univariable Cox proportional hazard models were used to evaluate the predictive value of clinical-pathological features on VER. A regularized Cox regression model was employed to build a predictive model of VER and recurrence within 12 months. The discriminant ability of the Cox regularized models was evaluated by reporting a ROC curve together with the calibration plot, considering 200 runs. Results: Among 1133 patients, 65 (16.0%) patients experienced a VER. Preoperative symptoms (HR 1.198), comorbidities (HR 1.289), tumor grade (HR 1.043), LNR (HR 4.339) and T stage (HR 1.639) were associated with an increased likelihood of VER. Model performance was very good at predicting VER at 6 months (AUC of 0.722) and 12 months (AUC 0.733). Two nomograms to predict 6-month and 12-month VER were built based on the predictive model. A higher nomogram score was associated with worse prognosis. There was good prediction between observed and estimated VER with minimal evidence of overfitting and good performance on internal bootstrapping validation. Conclusion: One in 6 patients experienced VER following curative-intent surgery for GC. Nomograms to predict risk of VER performed well on internal validation, and stratified patients into distinct prognostic groups relative to 6- and 12-months recurrence.
AB - Background: Recurrence after curative-intent surgery can occur in more than 50% of gastric cancer (GC) patients. We sought to identify predictors of very early recurrence (VER) among GC patients who underwent curative-intent surgery. Methods: A multi-institutional database of GC patients undergoing curative-intent surgery between 2000 and 2020 at 8 major institutions was queried. VER was defined as local or distant tumor recurrence within 6 months from surgery. Univariable Cox proportional hazard models were used to evaluate the predictive value of clinical-pathological features on VER. A regularized Cox regression model was employed to build a predictive model of VER and recurrence within 12 months. The discriminant ability of the Cox regularized models was evaluated by reporting a ROC curve together with the calibration plot, considering 200 runs. Results: Among 1133 patients, 65 (16.0%) patients experienced a VER. Preoperative symptoms (HR 1.198), comorbidities (HR 1.289), tumor grade (HR 1.043), LNR (HR 4.339) and T stage (HR 1.639) were associated with an increased likelihood of VER. Model performance was very good at predicting VER at 6 months (AUC of 0.722) and 12 months (AUC 0.733). Two nomograms to predict 6-month and 12-month VER were built based on the predictive model. A higher nomogram score was associated with worse prognosis. There was good prediction between observed and estimated VER with minimal evidence of overfitting and good performance on internal bootstrapping validation. Conclusion: One in 6 patients experienced VER following curative-intent surgery for GC. Nomograms to predict risk of VER performed well on internal validation, and stratified patients into distinct prognostic groups relative to 6- and 12-months recurrence.
UR - http://www.scopus.com/inward/record.url?scp=85136644448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136644448&partnerID=8YFLogxK
U2 - 10.1245/s10434-022-12434-y
DO - 10.1245/s10434-022-12434-y
M3 - Article
C2 - 36018525
AN - SCOPUS:85136644448
SN - 1068-9265
VL - 29
SP - 8653
EP - 8661
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 13
ER -